Could Amgen test Enbrel or other anti-TNF drugs against COVID-19? CEO Bradway drops a hint

As Amgen ramps up a clinical trial of its psoriasis drug Otezla in COVID-19, the company’s scientists may be seriously considering whether another of its blockbuster anti-inflammatories, Enbrel, could play a role in tamping down the virus.

CEO Robert Bradway hinted at that possibility during Fortune magazine’s Brainstorm Health virtual conference Tuesday.